Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
6.88
-0.02 (-0.29%)
Dec 5, 2025, 4:00 PM EST - Market closed
Cartesian Therapeutics Stock Forecast
RNAC's stock price has decreased by -68.73% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cartesian Therapeutics stock have an average target of 38.4, with a low estimate of 30 and a high estimate of 44. The average target predicts an increase of 458.14% from the current stock price of 6.88.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +336.05% | Nov 19, 2025 |
| BTIG | BTIG | Strong Buy Maintains $42 → $44 | Strong Buy | Maintains | $42 → $44 | +539.53% | Nov 14, 2025 |
| Wedbush | Wedbush | Buy Initiates $38 | Buy | Initiates | $38 | +452.33% | Jul 9, 2025 |
| Needham | Needham | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +481.40% | May 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +495.93% | Apr 9, 2025 |
Financial Forecast
Revenue This Year
2.02M
from 38.91M
Decreased by -94.81%
Revenue Next Year
686.02K
from 2.02M
Decreased by -66.06%
EPS This Year
-2.39
from -4.49
EPS Next Year
-3.44
from -2.39
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.4M | 2.0M | ||||
| Avg | 2.0M | 686,021 | ||||
| Low | 1.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -93.8% | -1.3% | ||||
| Avg | -94.8% | -66.1% | ||||
| Low | -95.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.33 | -2.75 | ||||
| Avg | -2.39 | -3.44 | ||||
| Low | -2.64 | -3.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.